Similarly, in prostate cancer, TOPK activates the β-catenin-TCF/LEF pathway, leading to upregulation of MMP-2 and MMP-9, both of which are associated with tumor invasion and metastasis 77, 85. This evidence concerns the gene MMP9 and neoplasm.